Therefore, the following review will focus on selected mediators implicatedin pulmonary vascular dysfunction and evidence that PPARs, in particular PPARγ, participate in their regulation and may providea potential novel therapeutic target for the treatment of pulmonary hypertension. This evidence concerns the gene PPARG and pulmonary hypertension.